| scholarly article | Q13442814 |
| P50 | author | Kyoung-Mee Kim | Q88377030 |
| P2093 | author name string | Ho Yeong Lim | |
| Se Hoon Park | |||
| Jeeyun Lee | |||
| Joon Oh Park | |||
| Seung Tae Kim | |||
| Won Ki Kang | |||
| Young Suk Park | |||
| Hee Kyung Kim | |||
| Hansang Lee | |||
| Mi Hwa Heo | |||
| P2860 | cites work | Targeting the hepatocyte growth factor-cMET axis in cancer therapy | Q24606259 |
| Changing international trends in mortality rates for liver, biliary and pancreatic tumours | Q33962674 | ||
| Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis | Q34745711 | ||
| Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma | Q35108386 | ||
| Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma | Q36614705 | ||
| Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. | Q36689648 | ||
| c-Met targeted therapy of cholangiocarcinoma | Q37169357 | ||
| Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival | Q38441644 | ||
| ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions | Q38455863 | ||
| Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials | Q39291910 | ||
| Overexpression of CD151 as an adverse marker for intrahepatic cholangiocarcinoma patients | Q39666724 | ||
| Is c-Met oncoprotein expression an adverse prognosticator in extrahepatic bile duct cancer treated with curative resection followed by adjuvant chemoradiotherapy? | Q41231601 | ||
| c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis. | Q44810921 | ||
| The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation | Q46580742 | ||
| MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas | Q46799794 | ||
| Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers | Q50539670 | ||
| c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. | Q52122642 | ||
| Targeting c-MET by LY2801653 for treatment of cholangiocarcinoma. | Q55032209 | ||
| The NanoString-based multigene assay as a novel platform to screen EGFR, HER2, and MET in patients with advanced gastric cancer. | Q55069791 | ||
| Precision Oncology: An Overview | Q61661587 | ||
| c-met mRNA overexpression in human hepatocellular carcinoma | Q72694068 | ||
| Expression of the c-met protooncogene in human hepatocellular carcinoma | Q72719873 | ||
| Clinical significance of hepatocyte growth factor and c-Met expression in extrahepatic biliary tract cancers | Q78056476 | ||
| Overexpression of c-Met and of the transducers PI3K, FAK and JAK in breast carcinomas correlates with shorter survival and neoangiogenesis | Q80429884 | ||
| Next-generation sequencing in precision oncology: challenges and opportunities | Q87801094 | ||
| P433 | issue | 8 | |
| P921 | main subject | ??? | Q18556397 |
| P304 | page(s) | 1395-1399 | |
| P577 | publication date | 2017-05-12 | |
| P1433 | published in | Journal of Cancer | Q6294901 |
| P1476 | title | The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC). | |
| P478 | volume | 8 |
| Q92486872 | Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets |
| Q100490609 | Overview of current targeted therapy in gallbladder cancer |
| Q64113657 | Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma |
Search more.